Embracing the new terrain.

The article focuses on the achievements of privately German owned company Boehringer Ingelheim (BI) GmbH which has continually produces safe and reliable products. It highlights the move of the company to invest and expand in the U.S. market. Furthermore, the approval given by the Food and Drug Administration (FDA) to Pradaxa, a drug indicated for the prevention of stroke and blood clots, has proven to be a turning point for the company's innovation.